Jacobs Levy Equity Management, Inc Regeneron Pharmaceuticals, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $23.9 Billion
- Q3 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 287,881 shares of REGN stock, worth $200 Million. This represents 0.68% of its overall portfolio holdings.
Number of Shares
287,881
Previous 234,267
22.89%
Holding current value
$200 Million
Previous $123 Million
31.61%
% of portfolio
0.68%
Previous 0.51%
Shares
12 transactions
Others Institutions Holding REGN
# of Institutions
1,466Shares Held
86.4MCall Options Held
2.42MPut Options Held
1.64M-
Vanguard Group Inc Valley Forge, PA9.05MShares$6.27 Billion0.08% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$5.86 Billion0.2% of portfolio
-
State Street Corp Boston, MA4.69MShares$3.25 Billion0.09% of portfolio
-
Dodge & Cox San Francisco, CA4.55MShares$3.16 Billion1.47% of portfolio
-
Jpmorgan Chase & CO New York, NY4.07MShares$2.82 Billion0.15% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $74.3B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...